We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
-19.74%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$275M
AUM Growth
-$16.9M
(-5.8%)
Cap. Flow
+$40.9M
Cap. Flow
% of AUM
14.91%
Top 10 Holdings %
Top 10 Hldgs %
36.4%
Holding
93
New
30
Increased
20
Reduced
14
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$11.5M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$11M |
| 3 |
CVS Health
CVS
|
+$10.8M |
| 4 |
Medtronic
MDT
|
+$8.96M |
| 5 |
Cardinal Health
CAH
|
+$7.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$14.6M |
| 2 |
AET
Aetna Inc
AET
|
+$12.3M |
| 3 |
Kura Oncology
KURA
|
+$7.72M |
| 4 |
Biogen
BIIB
|
+$6.82M |
| 5 |
Elevance Health
ELV
|
+$6.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.02% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Philips
PHG
$25.7B
| $1.76M | 0.64% |
64,415
-58,974
| -48% | -$1.74M |
|
|
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.66M | 0.6% |
17,000
-8,785
| -34% | -$1.04M |
|
|
LOGC
53
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $1.65M | 0.6% |
+158,958
| New | +$1.92M |
|
54
Inogen
INGN
$175M
| $1.59M | 0.58% |
+12,824
| New | +$2.11M |
|
|
CBAY
55
DELISTED
Cymabay Therapeutics
CBAY
| $1.47M | 0.54% |
+187,327
| New | +$1.78M |
|
56
Establishment Labs
ESTA
$2.72B
| $1.45M | 0.53% |
52,701
+8,023
| +18% | +$196K |
|
57
Senseonics Holdings Inc
SENS
$263M
| $1.24M | 0.45% |
23,993
+3,873
| +19% | +$259K |
|
58
Axsome Therapeutics
AXSM
$11.2B
| $1.07M | 0.39% |
380,812
-35,646
| -9% | -$117K |
|
|
IVC
59
DELISTED
Invacare Corporation
IVC
| $1.06M | 0.39% |
+247,196
| New | +$2.18M |
|
60
Veracyte
VCYT
$3.7B
| $883K | 0.32% |
+70,199
| New | +$830K |
|
61
Achieve Life Sciences
ACHV
$659M
| $723K | 0.26% |
29,869
+21,570
| +260% | +$814K |
|
|
PFNX
62
DELISTED
Pfenex Inc.
PFNX
| $681K | 0.25% |
213,608
| – | – |
|
|
TMDI
63
DELISTED
Titan Medical Inc. Ordinary Shares
TMDI
| $544K | 0.2% |
445,680
| – | – |
|
|
AFMD
64
DELISTED
Affimed
AFMD
| $503K | 0.18% |
16,164
-39,598
| -71% | -$1.47M |
|
|
CFMS
65
DELISTED
Conformis, Inc. Common Stock
CFMS
| $402K | 0.15% |
44,876
-29,596
| -40% | -$498K |
|
|
IMMU
66
DELISTED
Immunomedics Inc
IMMU
| $370K | 0.13% |
+25,900
| New | +$514K |
|
67
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
| $143K | 0.05% |
21,600
| – | – |
|
68
Actinium Pharmaceuticals
ATNM
$26.3M
| $132K | 0.05% |
+11,327
| New | +$193K |
|
69
Arbutus Biopharma
ABUS
$857M
| – | – |
-164,943
| Closed | -$1.56M |
|
70
CALL
Amgen
AMGN
$208B
| – | – |
-20,000
| Closed | -$4.15M |
|
71
Arrowhead Research
ARWR
$11.9B
| – | – |
-114,259
| Closed | -$2.19M |
|
72
PUT
AstraZeneca
AZN
$263B
| – | – |
-43,700
| Closed | -$3.46M |
|
|
73
Biogen
BIIB
$30B
| – | – |
-19,300
| Closed | -$6.82M |
|
74
electroCore
ECOR
$54.8M
| – | – |
-5,747
| Closed | -$1.21M |
|
|
75
Elevance Health
ELV
$81.5B
| – | – |
-24,803
| Closed | -$6.8M |
|
Similar funds
GUB
KLI
JA
WIC
AAM
TCM
CA
SAM
Sio Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Sio Capital Management held 93 positions worth $275M, down 5.8% from $291M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sio Capital Management deployed $40.9M of net new capital in Q4 2018, opening 30 new positions and adding to 20 existing holdings. Its largest new stake was Cencora: 133,934 shares worth $9.96M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 75% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Kura Oncology, an estimated $7.72M trimmed.
- Sio Capital Management's largest Q4 2018 buy was Cencora: 133,934 shares worth $9.96M.
- Sio Capital Management added most to Medtronic in Q4 2018, an estimated $8.96M increase.
- Sio Capital Management's biggest Q4 2018 reduction was Kura Oncology, cutting an estimated $7.72M.
- Sio Capital Management fully exited GSK in Q4 2018, selling an estimated $14.6M.
- Sio Capital Management's ten largest holdings make up 36% of its $275M portfolio in Q4 2018.
- Sio Capital Management opened 30 new positions and closed 25 in Q4 2018.
- Sio Capital Management's portfolio value fell 5.8% quarter-over-quarter to $275M.
Based on Sio Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.